Patent SG-11201810883T-A (SG)
Title: Combination therapy
Inventor: BONVINI EZIO
IPC: A61P31/00
Filed: 2017-06-06
Abstract: Tu mor Vo lu me (mm 3) 500: 400: 300: 200: 100: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 December 2017 (14.12.2017) WIP0 I PCT o n inn VIII Hu oimIE (10) International Publication Number WO 2017/214092 Al (51) International Patent Classification: A61K 39/395 (2006.01) A61P 35/00 (2006.01) C07K 16/28 (2006.01) A61P 31/00 (2006.01) (21) International Application Number: PCT/US2017/036075 (22) International Filing Date: 06 June 2017 (06.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/346,854 07 June 2016 (07.06.2016) US 62/432,299 09 December 2016 (09.12.2016) US (71) Applicant: MACROGENICS, INC. [US/US]; 9704 Med- ical Center Drive, Rockville, MD 20850 (US). (72) Inventors: BONVINI, Ezio; 11136 Powder Horn Drive, Potomac, MD 20854 (US). KOENIG, Scott; 10901 Ral- ston Road, Rockville, MD 20852 (US). JOHNSON, Leslie, S.; 14411 Poplar Hill Road, Darnestown, MD 20874 (US). MOORE, Paul, A.; 10 Turley Court, North Potomac, MD 20878 (US). ALDERSON, Ralph, F.; 13601 Query Mill Road, North Potomac, MD 20878 (US). (74) Agent: AUERBACH, Jeffrey, I. et al.; Auerbachschrot LLC, 2200 Research Blvd., Suite 560, Rockville, MD 20850 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (54) Title: COMBINATION THERAPY 7 0 0 7 0 5 10 15 20 25 30 35 Study Days -0- Vehicle -M- hPD-1 mAb7 (1.2) IgG4(P) -A- DART-A (CD3 x B7-H3) DART-A (CD3 x B7-H3) (Q7Dx5) -V- + hPD-1 mAb7 (1.2) IgG4(P) Figure 8A (57) : The present invention is directed to a combination therapy for the treatment of cancer and pathogen-associated diseases, that comprises the administration of: (I) a molecule (e.g., a diabody, an scFv, an antibody, a TandAb, etc.) capable of binding PD- I or a natural ligand of PD-I, and (2) a molecule (e.g., a diabody, a BiTe, a bispecific antibody, a CAR, etc.) capable of mediating the redirected killing of a target cell (e.g., a cancer cell or a pathogeninfected cell, etc.) expressing a Disease Antigen. The invention particularly concerns the embodiment in which the molecule capable of mediating the redirected killing of the target cell is a bispecific binding molecule that comprises a first epitope-binding site capable of immunospecifically binding an epitope of a cell surface molecule of an effector cell and a second epitope-binding site that is capable of immunospecifically binding an epitope of such target cells. [Continued on next page] WO 2017/214092 Al MIDEDIMOMMIMOIDEMODIDEIDIMEHOIHIMEMOIS PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))